Earnings

A Comparison of Top Movers: Clovis Oncology, Inc. (CLVS), Exelixis, Inc. (EXEL)

The shares of Clovis Oncology, Inc. have decreased by more than -18.35% this year alone. The shares recently went up by 5.85% or $3.07 and now trades at $55.52. The shares of Exelixis, Inc. (NASDAQ:EXEL), has slumped by -30.62% year to date as of 04/06/2018. The shares currently trade at $21.09 and have been able to report a change of -4.79% over the past one week.

The stock of Clovis Oncology, Inc. and Exelixis, Inc. were two of the most active stocks on Friday. Investors seem to be very interested in what happens to the stocks of these two companies but do investors favor one over the other? We will analyze the growth, profitability, risk, valuation, and insider trends of both companies and see which one investors prefer.

Profitability and Returns

Growth alone cannot be used to see if the company will be valuable. Shareholders will be the losers if a company invest in ventures that aren’t profitable enough to support upbeat growth. In order for us to accurately measure profitability and return, we will be using the EBITDA margin and Return on Investment (ROI), which balances the difference in capital structure. The ROI of CLVS is -27.30% while that of EXEL is 55.40%. These figures suggest that EXEL ventures generate a higher ROI than that of CLVS.

Cash Flow

The value of a stock is ultimately determined by the amount of cash flow that the investors have available. Over the last 12 months, CLVS’s free cash flow per share is a negative -0.12, while that of EXEL is positive 0.01.

Liquidity and Financial Risk



The ability of a company to meet up with its short-term obligations and be able to clear its longer-term debts is measured using Liquidity and leverage ratios. The current ratio for CLVS is 7.70 and that of EXEL is 4.20. This implies that it is easier for CLVS to cover its immediate obligations over the next 12 months than EXEL. The debt ratio of CLVS is 0.77 compared to 0.00 for EXEL. CLVS can be able to settle its long-term debts and thus is a lower financial risk than EXEL.

Valuation

CLVS currently trades at a P/B of 7.55, and a P/S of 50.02 while EXEL trades at a forward P/E of 16.45, a P/B of 21.97, and a P/S of 14.47. This means that looking at the earnings, book values and sales basis, CLVS is the cheaper one. It is very obvious that earnings are the most important factors to investors, thus analysts are most likely to place their bet on the P/E.

Analyst Price Targets and Opinions

The mistake some people make is that they think a cheap stock has more value to it. In order to know the value of a stock, there is need to compare its current price to its likely trading price in the future. The price of CLVS is currently at a -35.67% to its one-year price target of 86.30. Looking at its rival pricing, EXEL is at a -40.24% relative to its price target of 35.29.




When looking at the investment recommendation on say a scale of 1 to 5 (1 being a strong buy, 3 a hold, and 5 a sell), CLVS is given a 2.00 while 2.00 placed for EXEL. This means that analysts are equally bullish on their outlook for the two stocks stocks.

Insider Activity and Investor Sentiment

Short interest or otherwise called the percentage of a stock’s tradable shares currently being shorted is another data that investors use to get a handle on sentiment. The short ratio for CLVS is 5.98 while that of EXEL is just 4.18. This means that analysts are more bullish on the forecast for EXEL stock.

Conclusion

The stock of Clovis Oncology, Inc. defeats that of Exelixis, Inc. when the two are compared, with CLVS taking 4 out of the total factors that were been considered. CLVS happens to be more profitable, generates a higher ROI, has higher cash flow per share, higher liquidity and has a lower financial risk. When looking at the stock valuation, CLVS is the cheaper one on an earnings, book value and sales basis. Finally, the sentiment signal for CLVS is better on when it is viewed on short interest.

Previous ArticleNext Article

Related Post

Brooks Automation, Inc. (BRKS) Technical Analysis ... Brooks Automation, Inc. (NASDAQ:BRKS) gained 5.58% in yesterday’s trading session, going up from its prior closing price of $25.79 to $27.23 The stock...
Coty Inc. (COTY) Makes An Interesting Case Right N... Coty Inc. (NYSE:COTY) has recently been identified as an interesting stock but more in-depth monitoring is needed for a trade decision. Now trading wi...
Nova Lifestyle, Inc. (NVFY) and Leggett & Pla... Nova Lifestyle, Inc. (NASDAQ:NVFY) shares are up more than 26.94% this year and recently decreased -2.39% or -$0.06 to settle at $2.45. Leggett & ...
Critical Comparison: Zoetis Inc. (ZTS) vs. Lannett... Zoetis Inc. (NYSE:ZTS) shares are up more than 35.21% this year and recently increased 0.21% or $0.15 to settle at $72.38. Lannett Company, Inc. (NYSE...
Which of 2 stocks would appeal to long-term invest... The shares of ON Semiconductor Corporation have increased by more than 15.47% this year alone. The shares recently went up by 1.43% or $0.34 and now t...